← Alle ziektes Kanker

Longkanker (niet-kleincellig)

Automatisch bijgehouden uit PubMed en ClinicalTrials.gov, nieuwste bovenaan. Er verdwijnt hier nooit iets: wat je in je favorieten bewaart, blijft vindbaar. · RSS-feed van deze ziekte · alleen het zwaarste bewijs

Zoeken Periode Alle jarenLaatste 12 maandenLaatste 5 jaar Onderwerp Alle onderwerpenAlgemeenVoeding en dieetAlternatieve behandelwijzen Soort onderzoek Elk soort onderzoekAlleen het zwaarste bewijs (168)Meta-analyse (67)Behandelrichtlijn (1)Gerandomiseerd onderzoek (51)Systematisch overzicht (37)Fase 3-studie (12)Klinisch onderzoek (683)Overzichtsartikel (245)Vroege studie (fase 1 of 2) (27)Beschrijving van enkele patiënten (123)Laboratorium- of dieronderzoek (69)Commentaar of redactioneel (85)Ingetrokken publicatie (14)

Filteren

Publicaties en studies (3160)

• Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients. (2026/12/31) ♡
• Dietary intervention through bacterial-derived butyrate elicits anti-tumor activity and increases anti-PD-1 response. (2026/12/31) ♡
• Letter regarding 'clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations'. (2026/12/01) ♡
• Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRAS(G12C) and modulating the KRAS/AKT/ERK signaling axis. (2026/09/01) ♡
• OverzichtsartikeliEen samenvatting van wat er over een onderwerp bekend is, geschreven door deskundigen. Niet volgens vaste zoekregels samengesteld, dus de keuze van studies kan gekleurd zijn. Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy. (2026/09/01) ♡
• Feasibility of routine clinical liquid-based cytology for lung cancer compact panel testing. (2026/09/01) ♡
• Systemic inflammatory response and complications developing in patients undergoing lobectomy for non-small-cell lung cancer: thoracotomy versus video-assisted thoracoscopic surgery. (2026/09/01) ♡
• Construction of a survival prediction model and analysis of influencing factors for brain metastasis in non-small cell lung cancer based on multi‑parameter clinical data. (2026/08/10) ♡
• Is There Still Room for Monotherapy in EGFR-Mutated Non-Small Cell Lung Cancer? (2026/08/10) ♡
• Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. (2026/08/10) ♡
• Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary. (2026/08/10) ♡
• Liquid Biopsies for Cancer: A Translational Science Review. (2026/08/10) ♡
• Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. (2026/08/10) ♡
• MAGEA1 drives tumor progression via activation of the AKT pathway and correlates with elevated radiosensitivity in lung adenocarcinoma. (2026/08/10) ♡
• OverzichtsartikeliEen samenvatting van wat er over een onderwerp bekend is, geschreven door deskundigen. Niet volgens vaste zoekregels samengesteld, dus de keuze van studies kan gekleurd zijn. From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies. (2026/08/09) ♡
• Siglec-15 and PD-1 checkpoint blockade in combination with oncolytic Zika virus infection confers protection against immune-resistant gliomas. (2026/08/08) ♡
• Real-World Outcomes of Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Cohort Study From Vietnam. (2026/08/08) ♡
• Exploring multidimensional cfDNA methylation fragmentomics for non-invasive postoperative assessment in early-stage lung cancer. (2026/08/08) ♡
• Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis. (2026/08/08) ♡
• Salidroside Alleviates Mobocertinib-Induced Cardiotoxicity by Improving Cardiac Electrophysiology. (2026/08/08) ♡
• Clinical relative biological effectiveness of carbon-ion versus photon radiotherapy derived from tumor control probability models in locally advanced non-small cell lung cancer. (2026/08/08) ♡
• Lactate derived from CAFs mediates H3K18la in stemness gene promoters, which promotes tumor malignant phenotype formation. (2026/08/07) ♡
• Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan. (2026/08/07) ♡
• Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer. (2026/08/07) ♡
• A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor. (2026/08/07) ♡
• EZH1/2 inhibition selectively targets SMARCA4/2 co-deficient lung cancer cells by suppressing stemness and proliferation. (2026/08/07) ♡
• Artificial intelligence-powered evaluation of the pathologic response to preoperative therapy in non-small cell lung cancer. (2026/08/07) ♡
• [Rescue Resections in Thoracic Surgery for Septic Lung Carcinomas Undergoing Systemic Therapy: a Case Series]. (2026/08/07) ♡
• Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. (2026/08/07) ♡
• Clonal LIMD1 loss drives PD-L1 immune evasion via ARIH1-dependent ubiquitination in lung cancer. (2026/08/07) ♡
• Immune signatures in NSCLC associated pleural effusions and implications for prognosis. (2026/08/07) ♡
• Efficacy and Safety of Sintilimab in Combination With Anlotinib and Chemoradiotherapy as First-Line Treatment for Driver Gene-Negative Oligometastatic Non-small Cell Lung Cancer: A Real-World Cohort Study. (2026/08/07) ♡
• Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. (2026/08/06) ♡
• Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC. (2026/08/06) ♡
• Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. (2026/08/06) ♡
• OverzichtsartikeliEen samenvatting van wat er over een onderwerp bekend is, geschreven door deskundigen. Niet volgens vaste zoekregels samengesteld, dus de keuze van studies kan gekleurd zijn. A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. (2026/08/06) ♡
• SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. (2026/08/06) ♡
• Hypoxia-activated endothelial cells drive stemness and vasculogenic mimicry in NSCLC via a HIF-1α/ITPR3 axis. (2026/08/06) ♡
• De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study. (2026/08/06) ♡
• Preoperative prognostic nutritional index predicts overall survival in surgically resected small cell lung cancer: A single-institution experience. (2026/08/06) ♡
• Meta-analyseiAlle studies over één vraag bij elkaar opgeteld en samen doorgerekend. Dit is de sterkste manier van onderzoeken die er bestaat: één losse studie kan toeval zijn, tientallen samen veel minder. Het etiket zegt iets over de opzet, niet over de uitkomst — die kan ook zijn dat iets níét werkt. Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis. (2026/08/05) ♡
• Meta-analyseiAlle studies over één vraag bij elkaar opgeteld en samen doorgerekend. Dit is de sterkste manier van onderzoeken die er bestaat: één losse studie kan toeval zijn, tientallen samen veel minder. Het etiket zegt iets over de opzet, niet over de uitkomst — die kan ook zijn dat iets níét werkt. Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. (2026/08/05) ♡
• CD103+ tissue-resident T-cells in head and neck squamous cell carcinomas of patients treated anti-PD-1 therapy. (2026/08/05) ♡
• Commentaar of redactioneeliEen mening of toelichting van een deskundige, geen nieuw onderzoek. RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model. (2026/08/05) ♡
• CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes. (2026/08/05) ♡
• Dropout after Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer in the Veterans Health Administration. (2026/08/05) ♡
• Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report. (2026/08/05) ♡
• Perfluorononanoic acid enhances non-small cell lung cancer progression through CD36-driven fatty acid metabolic reprogramming. (2026/08/05) ♡
• OverzichtsartikeliEen samenvatting van wat er over een onderwerp bekend is, geschreven door deskundigen. Niet volgens vaste zoekregels samengesteld, dus de keuze van studies kan gekleurd zijn. [Management of chronic pulmonary GVH in 2025, indication for lung transplantation (SFGM-TC)]. (2026/08/05) ♡
• Efficacy and safety of adjuvant immunotherapy after pathological complete response following neoadjuvant chemoimmunotherapy in patients with resectable NSCLC: A real-world observational study. (2026/08/05) ♡

↑ Terug naar boven

codex.care geeft geen medisch advies. Bespreek klachten, medicatie en behandelkeuzes altijd met je eigen behandelaar.